Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | ||
| Arzerra | Ofatumumab | Chronic Lymphocytic Leukemia | Do not reimburse | Complete | ||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
| Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | ||
| Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | ||
| Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
| Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete |
Last Updated : May 19, 2024